Hassle-free Antibody Discovery

About Us

Experienced. Fast. Affordable.

At Immunovive, we strive to make a difference in the world of immunotherapeutics. Our mission is to accelerate life science research and biologics discovery by providing a high-quality antibody discovery service rapidly and affordably. Our BinderGenᵀᴹ lead discovery platform generates diverse in vivo-derived monoclonal antibody binders in 6 weeks designed to empower downstream drug development applications including target validation, proof-of-concept, lead optimization, and multimodality engineering. The Immunovive team brings decades of expertise, innovation, and leadership that has delivered success to thousands of biotherapeutic investigators worldwide. As a strictly fee-for-service preclinical CRO committed to mobilizing therapeutic ideas to proof-of-concept all rights to the resultant antibodies are 100% retained by the client.

Our Team

Devin E. Turner, Ph.D., Founder and CEO

After publishing his first transgenic strain in college Devin learned firsthand the transformative role innovation plays in research. He promptly pursued a Ph.D. working with unique humanized transgenic in vivo systems to study the role isotype-specific Fc receptors play in immune responses and subsequently led a small team at an antibody discovery startup in Cambridge, MA. Armed with a small nest egg and an idea to deliver on an unmet need in biotherapeutics research, Devin founded Abveris and created DiversimAbTM transgenic technology. After leading Abveris from a 1-person startup through substantial growth, hundreds of antibody campaigns, and an exit, Devin continues his passion for accelerating immunotherapeutics through his latest company, Immunovive, a company emboldened with the goal to meld knowledge, innovation, and expertise to help deliver the next generation of immunotherapies. In other roles, Devin served as the Head of Antibody Discovery at Abpro and at Alloy Therapeutics. Devin earned a B.S. in Molecular, Cellular, and Developmental Biology from UCLA and a Ph.D. in Immunology from Harvard Medical School. When Devin is not pushing the limits of drug discovery, he spends time with his family, perfecting BBQ, and visiting baseball parks.

Craig Bencsics, Ph.D., Head of In Vivo Antibody Discovery 

For over 25 years Craig has gained expertise in all facets of antibody discovery ranging molecular biology, mammalian cell culture, protein expression and purification, assay development and high throughput screening. At Tectonic Therapeutic, Craig managed a cross-functional team to isolate monoclonal antibodies via HTP hybridoma and single B cell isolation by flow cytometry. As Lead Scientist at the Dana Farber Cancer Institute Monoclonal Antibody Core (DFCI MAC), Craig consulted, designed, and executed hundreds of antibody discovery campaigns ranging many therapeutic areas and led the development of HTP variable region cloning and recombinant engineering. Working directly with the President and CSO, Craig helped develop the scientific strategy at GO Therapeutics, led a multitude of anti-glycopeptide campaigns, and developed critical reagents using CRISPR protocols. At Immunovive, Craig applies decades of experience and expertise culminating in an optimized research plan designed to rapidly deliver diverse sets of high-quality biotherapeutic lead molecules to the client. In his free time, you can find Craig spending time with his wife and daughter, watching movies (especially Chicago-based or sports movies), following Chicago and Boston sports teams, and listening to jazz and early R&B/soul music.